Meanwhile, pharmacological inhibiting FADS1 activity also demonstrated a dose-dependent response among non-brain cancer cells, and not in non-cancerous cells, suggesting that FADS1 is a potential novel target for anti-cancer treatment. The gene discussed is FADS1; the disease is cancer.